Personalized high-definition transcranial direct current stimulation for posterior cortical atrophy
Official title: Testing Personalized High Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy
Run by University of Michigan · NCT07191327 · Data updated 2026-11-12
This trial will test whether personalized HD-tDCS can improve visual and thinking abilities in people with posterior cortical atrophy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University of Michigan Academic / other |
| Locations | 1 site (Ann Arbor, Michigan) |
| Status | Recruiting |
| Started | January 28, 2026 |
| Main results expected | July 31, 2029 |
| Study ends | July 31, 2029 |
| Registry record updated | June 30, 2026 |
| Trial ID | NCT07191327 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with a diagnosis or symptoms consistent with posterior cortical atrophy who are fluent in English, medically compatible with HD-tDCS, and on stable relevant medications.
✕Probably not a fit
Patients with other primary neurological disorders (e.g., epilepsy, large-vessel stroke, moderate–severe TBI), active major psychiatric illness, recent substance or alcohol abuse, or who are incompatible with HD-tDCS are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, sham-controlled protocol gives participants either real or sham HD-tDCS across eight sessions over four days, followed by an optional open-label phase of real HD-tDCS extending up to 26 weeks. Imaging (fMRI and PET/CT) and standardized memory, visual, and computerized cognitive tests are used before and after treatment to measure change. The approach uses individualized stimulation targeting and compares active stimulation to a placebo-like sham. Remote long-term visits are possible but require a study partner to administer stimulation at home, and participants must meet language and medical compatibility requirements.
Why it matters
Potential benefit: If successful, this could offer a noninvasive option to improve visual processing and cognitive function for people with PCA.
How similar studies have gone: Smaller tDCS studies in related dementia and visual-processing conditions have shown mixed, preliminary results, so personalized HD-tDCS is promising but remains experimental for PCA.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis or symptoms consistent with PCA * Fluent in English * HD-tDCS compatible * Stable on relevant medications for at least approximately 4 weeks prior to study enrollment * If completing any additional, optional, long-term study visits in a remote location (i.e., not our office), a study partner is required in order to administer HD-tDCS. Those choosing to return to our office may have, but are not required to have, a study partner. Exclusion Criteria: * Other relevant neurological disease (e.g., epilepsy) or injuries (e.g., large vessel stroke, moderate-severe traumatic brain injury) viewed as primary to deficits since these could interfere with etiologic considerations and confound study results * Active, relevant psychiatric conditions (e.g., bipolar disorder, schizophrenia) since the symptoms of these conditions may confound study participation. * A recent (e.g., within the past 2 years) significant history of, or current, alcohol or drug abuse/dependence. Remote history of abuse/dependence is not exclusionary as long as it is not considered to be the primary etiology for visuospatial deficits. * Women that are lactating/breastfeeding, pregnant, or may potentially be pregnant will be excluded from the study.
Where it's running
-
University of Michigan
Ann Arbor, Michigan, United States Recruiting
Study contacts
- Principal investigator: Benjamin Hamstead, PhD — University of Michigan
- Study coordinator: Stephen Schlaefflin, BS
- Email: schlst@umich.edu
- Phone: 734-936-7360
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding brain resilience in Alzheimer's disease and its variants
This study is trying to understand how some people with Alzheimer's disease, especially those with early symptoms, can stay resilient and cope better by looking at their brain scans and thinking abilities.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
Powered vs Manual Toothbrushes for Kids: Does it affect Cavity Risk?
This study tests whether using a powered toothbrush twice daily for a year lowers cavity risk in kids aged 8–12 compared with a standard manual brush, using fluoride toothpaste as the control.
-
PIONEER-Prognosis: Using biomarkers and wearables to forecast recovery after mild traumatic brain injury
This study tests whether blood biomarkers, health data from records, and wearables can help predict how people recover after a mild traumatic brain injury treated in the emergency department.
-
Sex hormones, menopause, and exercise in aging women
This study tests how hormonal status and resistance training affect age-related muscle and nerve function in postmenopausal women.
-
RENEW: a digital program to help people with axial spondyloarthritis manage energy and symptoms
A web-based, peer-led program called RENEW is tested to see if people with axial spondyloarthritis can easily use it, like it, and benefit from it in managing fatigue and symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.